USRE38919E1 - Injectable microfoam containing a sclerosing agent - Google Patents

Injectable microfoam containing a sclerosing agent Download PDF

Info

Publication number
USRE38919E1
USRE38919E1 US10/458,806 US45880603A USRE38919E US RE38919 E1 USRE38919 E1 US RE38919E1 US 45880603 A US45880603 A US 45880603A US RE38919 E USRE38919 E US RE38919E
Authority
US
United States
Prior art keywords
microfoam
injectable
substance
sclerosing
injecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/458,806
Inventor
Juan Cabrera Garrido
Juan Cabrera Garcia-Olmedo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8282315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE38919(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BTG International Ltd filed Critical BTG International Ltd
Priority to US10/458,806 priority Critical patent/USRE38919E1/en
Priority to US10/941,013 priority patent/USRE40640E1/en
Application granted granted Critical
Publication of USRE38919E1 publication Critical patent/USRE38919E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/07—Microporous membranes

Definitions

  • SchlerosisSclerosis of varices is based on injecting liquid substances in them, which causing a localized inflammatory reaction propitiates the elimination of these abnormal veins.
  • a mixture thereof with the blood contained in the vein is produced and diluted in an unknown proportion.
  • the results are uncertain (due to overdose or underdose) and limited to short varicose segments.
  • the size of the varices to be injected decreases, the lesser this dilution is and the results that are obtained are more foreseeable.
  • sclerosis is a technique chosen in cases of small and medium-sized varices. Surgery is used for those varices with a diameter equal to larger than 7 mm.
  • Orbach In 1946 Orbach injected in small caliber varices some few cubic centimeters of air and verified displacement of the blood inside the vessel, which is occupied by the injected air.
  • the sclerosing agent introduced afterwards is more effective than if it has been injected into the blood.
  • This invention refers to the preparation of a sclerosing microfoam.
  • the lifting of the injected member decreases even more the venous pressure, facilitating the exclusive filling of the vein with microfoam; this remaining in the vessel while the patient is not lifted from the examination table.
  • microfoam prepared with a sclerosing agent Upon replacing the prepared microfoam with the physiological serum by microfoam prepared with a sclerosing agent and injecting it in the vein, this displaces the blood that the vein contains and guarantees the contact of the sclerosis agent with the endothelium of the vein, at a known concentration and for a controllable amount of time, achieving sclerosis of the entire occupied segment.
  • the elaboration of the present invention is carried out with the preparation of a microfoam with any sclerosing agent, such as: polydocanol polidocanol, sodium tetradecly tetradecyl sulfate, hypertonic glucosated or glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, iodated solutions.
  • any sclerosing agent such as: polydocanol polidocanol, sodium tetradecly tetradecyl sulfate, hypertonic glucosated or glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, iodated solutions.
  • the sclerosing microfoam has been prepared by any one of the existing processes, two of which will be described hereinafter, it is introduced in any sterile vessel that can be used later to be injected in the vessels to be treated, and that permits the stability of the same, so that it can be removed by a syringe, or by any other instrument that allows injection thereof into the vessels to be treated.
  • the preparation of the sclerosing microfoam is done by mixing in a sterile, hermetic container and connected if desired to a bottle under oxygen pressure, mixture of oxygen and carbon dioxide or other physiological gasses gases; mechanical beating is carried out by means of a micromotor that makes an écouvillon submerged in the sclerosing solution to be foamed turn.
  • the microfoam is achieved.
  • the sclerosing agent does not have a foaming capacity Polysorbate 20, Polysorbate 80, Polygeline or any other substance with a foaming capacity accepted as inert for intravenous use is added to it.
  • the sclerosing agent is introduced into a hermetic, pressurized and sterile container and by stirring the solution the microfoam is achieved, with a outlet from the container for its subsequent use.
  • the invention can also embrace prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance.
  • the sclerosing substanc in the injectable microfoam is polidocanol.
  • it is sodium tetradecyl sulfate.
  • it is a hypertonic glucostated or glucosaline solution.
  • the sclerosing substance can be chromated glycerol.
  • the sclerosing substance in another embodiment is ethanolamine oleate.
  • Another embodiment could envisage sodium morrhuate as the sclerosing substance.
  • the present invention also uses the inventive microfoam in phlebology.
  • the sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
  • the present invention also uses the inventive microfoam in the treatment of esophageal varices.
  • the sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
  • the present invention also uses the inventive microfoam in a proctology.
  • the sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
  • the present invention also uses the inventive microfoam in angiology.
  • the sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.

Abstract

Injectable microfoam for sclerotcraphy. The sclerotherapy of varices is based on the injection of liquid substances capable of suppressing them. The present invention relates to the preparation of sclerosing substances in the form of a microfoam. The microfoam is prepared with sclerosing agents, and is then injected in the vein to be treated, so that the microfoam displaces the blood contained in the vein and provides for the contact of the sclerosing agent with the vascular endothelium, with a predetermined known concentration and during a controllable time.

Description

This is a continuation of international application Serial No. PCT/ES94/00064, filed Jun. 21, 1994.
PRIOR ART
SchlerosisSclerosis of varices is based on injecting liquid substances in them, which causing a localized inflammatory reaction propitiates the elimination of these abnormal veins.
Upon injecting a sclerosing agent, a mixture thereof with the blood contained in the vein is produced and diluted in an unknown proportion. The results are uncertain (due to overdose or underdose) and limited to short varicose segments. As the size of the varices to be injected decreases, the lesser this dilution is and the results that are obtained are more foreseeable. Nowadays, sclerosis is a technique chosen in cases of small and medium-sized varices. Surgery is used for those varices with a diameter equal to larger than 7 mm.
Sclerosis and surgery complement each other at this time, but sclerotherapy continues without being able to be applied to large varicose trunci.
In these large sized varices, upon injecting a sclerosing substance, the concentration thereof in the vein, its homogenous distribution in the blood and the time that it is going to be in contact with the inside walls of the treted treated vein are unknown.
In 1946 Orbach injected in small caliber varices some few cubic centimeters of air and verified displacement of the blood inside the vessel, which is occupied by the injected air. The sclerosing agent introduced afterwards is more effective than if it has been injected into the blood.
In thick varices, upon injecting air, the described phenomenon of displacement of the blood by the injected air does not take place, but rather this forms a bubble inside the vein that makes the process ineffective in these vessels.
This same author conceived, a few years late later, injection of foam obtained by agitating in a container containing sodium tetradecyl sulfate, an anionic sclerosing detergent with a high foaming capacity.
The process turns out to be rather useless due to the large-sized bubbles formed and dangerous due to the collateral effects of the atmospheric nitrogen, not very soluble in blood.
Both methods had very little practical repercussion as they were used only in small varices.
DESCRIPTION OF THE INVENTION
This invention refers to the preparation of a sclerosing microfoam.
In accordance with the present invention it has been discovered that injecting in a horizontal position a microfoam of pharmacologically inert sterile physiological serum, it is verified that the microfoam causes displacement of the blood contained in the vessel, even in more developed varices, due to the fact that the pressure of the blood contained in them horizontally is low.
The lifting of the injected member decreases even more the venous pressure, facilitating the exclusive filling of the vein with microfoam; this remaining in the vessel while the patient is not lifted from the examination table.
Upon replacing the prepared microfoam with the physiological serum by microfoam prepared with a sclerosing agent and injecting it in the vein, this displaces the blood that the vein contains and guarantees the contact of the sclerosis agent with the endothelium of the vein, at a known concentration and for a controllable amount of time, achieving sclerosis of the entire occupied segment.
The advantages of this process allow:
1. To know the concentration of the sclerosing agent in the vessel, as the microfoam displaces the blood and is not diluted in it like a liquid in it.
2. To guarantee the homogenous distribution of the product of sclerosis in the inside thereof.
3. To control the time in which it is kept in contact with the inside walls of the vein.
All of these factors are not known exactly nor are they controllable with the use of liquid sclerosing agents.
The elaboration of the present invention is carried out with the preparation of a microfoam with any sclerosing agent, such as: polydocanol polidocanol, sodium tetradecly tetradecyl sulfate, hypertonic glucosated or glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, iodated solutions.
Once the sclerosing microfoam has been prepared by any one of the existing processes, two of which will be described hereinafter, it is introduced in any sterile vessel that can be used later to be injected in the vessels to be treated, and that permits the stability of the same, so that it can be removed by a syringe, or by any other instrument that allows injection thereof into the vessels to be treated.
EXAMPLE 1
The preparation of the sclerosing microfoam is done by mixing in a sterile, hermetic container and connected if desired to a bottle under oxygen pressure, mixture of oxygen and carbon dioxide or other physiological gasses gases; mechanical beating is carried out by means of a micromotor that makes an écouvillon submerged in the sclerosing solution to be foamed turn.
Beating between 8,000 and 15,000 rpm, for a time between 60 and 120 seconds, the microfoam is achieved.
This is introduced into any container that can be used for subsequent storage and later injection into the veins to be sclerosed.
In the event that the sclerosing agent does not have a foaming capacity Polysorbate 20, Polysorbate 80, Polygeline or any other substance with a foaming capacity accepted as inert for intravenous use is added to it.
EXAMPLE 2
The sclerosing agent is introduced into a hermetic, pressurized and sterile container and by stirring the solution the microfoam is achieved, with a outlet from the container for its subsequent use.
The invention can also embrace prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance. In one embodiment, the sclerosing substanc in the injectable microfoam is polidocanol. In another embodiment, it is sodium tetradecyl sulfate. In a further embodiment, it is a hypertonic glucostated or glucosaline solution. In still another embodiment, the sclerosing substance can be chromated glycerol. The sclerosing substance in another embodiment is ethanolamine oleate. Another embodiment could envisage sodium morrhuate as the sclerosing substance. Still another, envisages any iodated solution.
The present invention also uses the inventive microfoam in phlebology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
The present invention also uses the inventive microfoam in the treatment of esophageal varices. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
The present invention also uses the inventive microfoam in a proctology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.
The present invention also uses the inventive microfoam in angiology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.

Claims (36)

1. Prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance.
2. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance is polydocanol.
3. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance is sodium tetradecyl sulfate.
4. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance is a hypertonic glucostated by glucosaline solution.
5. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is chromated glycerol.
6. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is ethanolamine oleate.
7. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is sodium morrhuate.
8. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is any iodated solution.
9. A method for phlebologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.
10. A method for phlebologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.
11. A method for phlebologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.
12. A method for treatment of esophageal varices comprising injecting the microfoam of claim 1 into vessels to be treated.
13. A method for treatment of esophageal varices comprising injecting the microfoam of claim 2 into vessels to be treated.
14. A method for treatment of esophageal varices comprising injecting the microfoam of claim 3 into vessels to be treated.
15. A method for proctologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.
16. A method for proctologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.
17. A method for proctologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.
18. A method for angiologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.
19. A method for angiologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.
20. A method for angiologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.
21. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made in a container under pressure of oxygen.
22. The injectable microfoam of claim 21, wherein the at least one sclerosing substance is polidocanol.
23. The injectable microfoam of claim 21, wherein the microfoam further comprises at least one substance with a foaming capacity.
24. The injectable microfoam of claim 23, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
25. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made in a container under pressure of a mixture of oxygen and carbon dioxide.
26. The injectable microfoam of claim 25, wherein the at least one sclerosing substance is polidocanol.
27. The injectable microfoam of claim 25, wherein the microfoam further comprises at least one substance with a foaming capacity.
28. The injectable microfoam of claim 27, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
29. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made under pressure of oxygen in a hermetic container.
30. The injectable microfoam of claim 29, wherein the at least one sclerosing substance is polidocanol.
31. The injectable microfoam of claim 29, wherein the microfoam further comprises at least one substance with a foaming capacity.
32. The injectable microfoam of claim 31, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
33. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made under pressure of a mixture of oxygen and carbon dioxide in a hermetic container.
34. The injectable microfoam of claim 33, wherein the at least one sclerosing substance is polidocanol.
35. The injectable microfoam of claim 33, wherein the microfoam further comprises at least one substance with a foaming capacity.
36. The injectable microfoam of claim 35, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
US10/458,806 1993-06-23 2003-06-11 Injectable microfoam containing a sclerosing agent Expired - Lifetime USRE38919E1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/458,806 USRE38919E1 (en) 1993-06-23 2003-06-11 Injectable microfoam containing a sclerosing agent
US10/941,013 USRE40640E1 (en) 1993-06-23 2004-09-15 Injectable microfoam containing a sclerosing agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES09301413A ES2068151B1 (en) 1993-06-23 1993-06-23 INJECTABLE MICROS FOAM FOR SCLEROSIS.
PCT/ES1994/000064 WO1995000120A1 (en) 1993-06-23 1994-06-21 Injectable microfoam containing a sclerosing agent
US08/407,595 US5676962A (en) 1993-06-23 1995-02-23 Injectable microfoam containing a sclerosing agent
US10/458,806 USRE38919E1 (en) 1993-06-23 2003-06-11 Injectable microfoam containing a sclerosing agent

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/ES1994/000064 Continuation WO1995000120A1 (en) 1993-06-23 1994-06-21 Injectable microfoam containing a sclerosing agent
US08/407,595 Reissue US5676962A (en) 1993-06-23 1995-02-23 Injectable microfoam containing a sclerosing agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/407,595 Continuation US5676962A (en) 1993-06-23 1995-02-23 Injectable microfoam containing a sclerosing agent

Publications (1)

Publication Number Publication Date
USRE38919E1 true USRE38919E1 (en) 2005-12-13

Family

ID=8282315

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/407,595 Ceased US5676962A (en) 1993-06-23 1995-02-23 Injectable microfoam containing a sclerosing agent
US10/458,806 Expired - Lifetime USRE38919E1 (en) 1993-06-23 2003-06-11 Injectable microfoam containing a sclerosing agent
US10/941,013 Expired - Lifetime USRE40640E1 (en) 1993-06-23 2004-09-15 Injectable microfoam containing a sclerosing agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/407,595 Ceased US5676962A (en) 1993-06-23 1995-02-23 Injectable microfoam containing a sclerosing agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/941,013 Expired - Lifetime USRE40640E1 (en) 1993-06-23 2004-09-15 Injectable microfoam containing a sclerosing agent

Country Status (9)

Country Link
US (3) US5676962A (en)
EP (1) EP0656203B3 (en)
AT (1) ATE179598T1 (en)
AU (1) AU7001294A (en)
DE (1) DE69418286T2 (en)
DK (1) DK0656203T3 (en)
ES (2) ES2068151B1 (en)
GR (1) GR3030248T3 (en)
WO (1) WO1995000120A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156915A1 (en) * 2000-11-24 2004-08-12 Harman Anthony David Generation of therapeutic microfoam
US20060049269A1 (en) * 1999-05-26 2006-03-09 Tariq Osman Generation of therapeutic microfoam
US20060062736A1 (en) * 2003-11-17 2006-03-23 Wright David D I Therapeutic foam
US20070003489A1 (en) * 2003-11-17 2007-01-04 Wright David D I Therapeutic foam
US20080031827A1 (en) * 2001-08-08 2008-02-07 Maria Garcia-Olmedo Dominguez Injectables in foam. New Pharmaceutical applications
US20090124704A1 (en) * 2005-05-13 2009-05-14 William John Jenkins Therapeutic foam
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2068151B1 (en) 1993-06-23 1995-11-16 Cabrera Garrido Juan INJECTABLE MICROS FOAM FOR SCLEROSIS.
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
AU2005205772B2 (en) * 1999-05-26 2009-04-30 Btg International Limited Generation of Therapeutic Microfoam
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7077836B2 (en) * 2000-07-21 2006-07-18 Vein Rx, Inc. Methods and apparatus for sclerosing the wall of a varicose vein
US20030120256A1 (en) * 2001-07-03 2003-06-26 Syntheon, Llc Methods and apparatus for sclerosing the wall of a varicose vein
GB2369996B (en) * 2000-12-18 2004-06-23 S T D Pharmaceutical Products Method and apparatus for producing an injectable foam
DE60142311D1 (en) * 2001-08-08 2010-07-15 Dominguez Maria Antonia Garcia-Olmedo INJECTABLE FOAM AND NEW PHARMACEUTICAL APPLICATIONS THEREFOR
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US20050172232A1 (en) * 2002-03-28 2005-08-04 Wiseman Richard M. Synchronisation in multi-modal interfaces
GB0212047D0 (en) 2002-05-24 2002-07-03 Btg Int Ltd Generation of therapeutic microfoam
GB0300586D0 (en) * 2003-01-10 2003-02-12 Btg Int Ltd Therapeutic microfoam
ES2216708B1 (en) * 2003-04-08 2006-02-16 Antonio Luis Cabrera Garrido "AWESOME SOLUTION".
US7314466B2 (en) * 2003-10-02 2008-01-01 Lary G Banning Minimally invasive vascular surgery
ES2247898B1 (en) * 2003-12-18 2006-12-01 Universidad Complutense De Madrid USE OF A PRIOR POLYCHOCAMOL INJECTION IN THE FORM OF MICROSPUMA FOR THE PAINLESS REMOVAL OF VARICES THROUGH LASER.
ITMI20041056A1 (en) * 2004-05-26 2004-08-26 Garrido Antonio Luis Cabrera USE IN THE DIAGNOSTIC MEDICAL FIELD AND LOGICAL FLEBUS OF A KISCELA OF STERILE AND PHYSIOLOGICALLY ACCEPTABLE GASES
EP1835958A1 (en) * 2005-01-14 2007-09-26 Vein RX Inc. Valve system for a medical device having an inflatable member
WO2007114934A2 (en) * 2006-04-04 2007-10-11 Vnus Medical Technologies, Inc. Method and apparatus for generating vascular treatment foam
EP2043531B1 (en) 2006-06-15 2013-01-02 Cook Medical Technologies LLC Systems and devices for the delivery of endoluminal prostheses
US20080050436A1 (en) * 2006-08-25 2008-02-28 Chu Jack F Methods and compounds for obliteration of vessels
US20190070397A1 (en) * 2006-11-27 2019-03-07 Frank Levy Apparatus and method for producing co2 enriched medical foam
ES2402904T3 (en) 2006-12-21 2013-05-10 Btg International Limited Device and method for producing therapeutic foam
WO2009036250A1 (en) 2007-09-12 2009-03-19 Cook Incorporated Enhanced remodelable materials for occluding bodily vessels and related methods and systems
US8157747B2 (en) 2008-02-15 2012-04-17 Lary Research & Development, Llc Single-use indicator for a surgical instrument and a surgical instrument incorporating same
CA2753207C (en) 2009-02-20 2017-07-11 Sapheon, Inc. Methods and devices for venous occlusion for the treatment of venous insufficiency
US9427233B2 (en) 2011-06-06 2016-08-30 Cook Medical Technologies, LLC Vascular occlusion devices and methods
WO2013013080A1 (en) 2011-07-20 2013-01-24 Sapheon, Inc. Enhanced ultrasound visualization of intravascular devices
US8808620B1 (en) 2012-02-22 2014-08-19 Sapheon, Inc. Sterilization process design for a medical adhesive
JP2012246306A (en) * 2012-08-22 2012-12-13 Btg Internatl Ltd Injectable foam preparation, and new pharmaceutical application
CN105899136A (en) 2014-01-07 2016-08-24 柯惠有限合伙公司 Cyanoacrylate compositions including non-agglomerating radiopaque nanoparticles
WO2015185554A2 (en) 2014-06-03 2015-12-10 Enrique Roche Rebollo Methods, devices, systems and kits for preparing compositions for care and repair of varicose veins
EP2962681A1 (en) 2014-07-03 2016-01-06 Swiss VX Venentherapie und Forschung GmbH Devices and methods for injectable vascular sclerofoams using a carrier made of human blood and uses thereof
US20160045416A1 (en) * 2014-08-14 2016-02-18 John Daniel Dobak Ethanolamine oleate formulations for treatment of adipose tissue
GB201611778D0 (en) 2016-07-06 2016-08-17 Provensis Ltd Method and device for producing foam
GB201612925D0 (en) * 2016-07-26 2016-09-07 Provensis Ltd Method and device for generating injectable foam
US11109867B2 (en) 2018-03-16 2021-09-07 Boston Scientific Scimed, Inc. Devices and methods for vein closure
IT201800006109A1 (en) 2018-06-07 2019-12-07 POLIDOCANOL FOR USE AS AN IMMUNOMODULATOR
US11911581B1 (en) 2022-11-04 2024-02-27 Controlled Delivery Systems, Inc. Catheters and related methods for the aspiration controlled delivery of closure agents

Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1547768A (en) 1967-10-09 1968-11-29 Fillable container with pressure relief device
US3698453A (en) 1970-09-01 1972-10-17 Oreal Device for storing two liquids separately and dispensing them simultaneously under pressure
US3970219A (en) 1975-03-03 1976-07-20 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols and process
US4019657A (en) 1975-03-03 1977-04-26 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols
US4040420A (en) 1976-04-22 1977-08-09 General Dynamics Packaging and dispensing kit
US4127131A (en) 1977-06-20 1978-11-28 Johnson & Johnson Hub assembly for use in the filtration of fluids and method of making the same
US4276885A (en) 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4292972A (en) 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
EP0054728A1 (en) 1980-12-23 1982-06-30 Intermedicat Gmbh Catheter assembly
DE3048744A1 (en) 1980-12-23 1982-07-22 Metzeler Kautschuk GmbH, 8000 München Multiple window pane sealed to timber frame - with elastomer strip and sealing cpd. laid in groove of elastomer
EP0077752A2 (en) 1981-10-16 1983-04-27 Schering Aktiengesellschaft Liquid mixture for absorbing and stabilizing gas bubbles to be used as contrast agent in ultrasonic diagnosis and process for its preparation
EP0123235A2 (en) 1983-04-15 1984-10-31 Schering Aktiengesellschaft Microparticles and ultrasonic contrast means containing gas bubbles
EP0131540A2 (en) 1983-07-06 1985-01-16 Schering Aktiengesellschaft Contrast agent for ultrasounds and its preparation
DE3050812C2 (en) 1980-12-23 1985-03-21 B. Braun Melsungen Ag, 3508 Melsungen Catheterization device
EP0217582A2 (en) 1985-09-16 1987-04-08 Unilever Plc Package for mixing and dispensing
DE8704600U1 (en) 1987-03-27 1987-10-15 Cocon Kunststoffen B.V., Arkel, Nl
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3417182C2 (en) 1984-05-09 1989-01-19 Gerald Dr. 8000 Muenchen De Hauer
EP0324938A1 (en) 1987-12-29 1989-07-26 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
EP0359246A2 (en) 1988-09-14 1990-03-21 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
US5064103A (en) 1990-05-23 1991-11-12 Rjs Industries, Inc. Foam dispenser having a plurality of sieves
US5084011A (en) 1990-01-25 1992-01-28 Grady Daniel J Method for oxygen therapy using hyperbarically oxygenated liquid
WO1992005806A1 (en) * 1990-10-05 1992-04-16 Sintetica S.A. Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography
FR2672038A1 (en) 1991-01-25 1992-07-31 Oreal Device for dispensing foam from a pressurised container
US5141738A (en) 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
WO1995000120A1 (en) 1993-06-23 1995-01-05 Juan Cabrera Garrido Injectable microfoam containing a sclerosing agent
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
WO1996025194A1 (en) 1995-02-17 1996-08-22 Durand Limited Medication and apparatus and method of applying medication
US5623085A (en) 1994-09-23 1997-04-22 Rohm And Haas Company Method for reducing microfoam in a spray-applied waterborne composition
US5656200A (en) 1993-01-23 1997-08-12 Henkel Kommanditgesellschaft Auf Aktien Foaming emulsions
US5902225A (en) 1994-10-11 1999-05-11 Monson; James A. Post foamable multiple-sequential-foaming composition
WO1999043371A1 (en) 1998-02-27 1999-09-02 Alain Monfreux Device for producing foam in a syringe body
FR2775436A1 (en) 1998-02-27 1999-09-03 Alain Monfreux Syringe for parenteral administration of substance in foam form
EP0997396A1 (en) 1998-10-28 2000-05-03 Kurt Vogelsang GmbH Cap for two-components aerosol container
WO2000024649A1 (en) 1997-05-07 2000-05-04 Giltech Limited Packaging system for mixing and dispensing multicomponent products
WO2000066274A1 (en) 1999-05-03 2000-11-09 Francisco Javier Garcia Mingo Device for producing foamed sclerosing agent
WO2000072821A1 (en) 1999-05-26 2000-12-07 Btg International Limited Generation of therapeutic microfoam
US6561237B1 (en) 2000-11-28 2003-05-13 Brasscorp Ltd. Apparatus and method for urging fluid into a pressurized system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3955720A (en) 1972-11-15 1976-05-11 Malone David C Low pressure dispensing apparatus with air pump
CH676456A5 (en) 1988-04-05 1991-01-31 Supermatic Kunststoff Ag
NL9300517A (en) 1993-03-23 1994-10-17 Airspray Int Bv Foam forming assembly, a suitable spray head and a spray can comprising such an assembly.

Patent Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1547768A (en) 1967-10-09 1968-11-29 Fillable container with pressure relief device
US3698453A (en) 1970-09-01 1972-10-17 Oreal Device for storing two liquids separately and dispensing them simultaneously under pressure
US3970219A (en) 1975-03-03 1976-07-20 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols and process
US4019657A (en) 1975-03-03 1977-04-26 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols
US4040420A (en) 1976-04-22 1977-08-09 General Dynamics Packaging and dispensing kit
US4127131A (en) 1977-06-20 1978-11-28 Johnson & Johnson Hub assembly for use in the filtration of fluids and method of making the same
US4276885A (en) 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4292972A (en) 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
EP0054728A1 (en) 1980-12-23 1982-06-30 Intermedicat Gmbh Catheter assembly
DE3048744A1 (en) 1980-12-23 1982-07-22 Metzeler Kautschuk GmbH, 8000 München Multiple window pane sealed to timber frame - with elastomer strip and sealing cpd. laid in groove of elastomer
DE3050812C2 (en) 1980-12-23 1985-03-21 B. Braun Melsungen Ag, 3508 Melsungen Catheterization device
EP0077752A2 (en) 1981-10-16 1983-04-27 Schering Aktiengesellschaft Liquid mixture for absorbing and stabilizing gas bubbles to be used as contrast agent in ultrasonic diagnosis and process for its preparation
US4466442A (en) * 1981-10-16 1984-08-21 Schering Aktiengesellschaft Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
EP0123235A2 (en) 1983-04-15 1984-10-31 Schering Aktiengesellschaft Microparticles and ultrasonic contrast means containing gas bubbles
CA1232837A (en) 1983-04-15 1988-02-16 Jurgen Hilmann Ultrasound contrast agent containing microparticles and gas micro-bubbles
US5141738A (en) 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
EP0131540A2 (en) 1983-07-06 1985-01-16 Schering Aktiengesellschaft Contrast agent for ultrasounds and its preparation
DE3417182C2 (en) 1984-05-09 1989-01-19 Gerald Dr. 8000 Muenchen De Hauer
EP0217582A2 (en) 1985-09-16 1987-04-08 Unilever Plc Package for mixing and dispensing
DE8704600U1 (en) 1987-03-27 1987-10-15 Cocon Kunststoffen B.V., Arkel, Nl
EP0324938A1 (en) 1987-12-29 1989-07-26 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
EP0359246A2 (en) 1988-09-14 1990-03-21 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5084011A (en) 1990-01-25 1992-01-28 Grady Daniel J Method for oxygen therapy using hyperbarically oxygenated liquid
US5064103A (en) 1990-05-23 1991-11-12 Rjs Industries, Inc. Foam dispenser having a plurality of sieves
WO1992005806A1 (en) * 1990-10-05 1992-04-16 Sintetica S.A. Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography
FR2672038A1 (en) 1991-01-25 1992-07-31 Oreal Device for dispensing foam from a pressurised container
US5656200A (en) 1993-01-23 1997-08-12 Henkel Kommanditgesellschaft Auf Aktien Foaming emulsions
US5676962A (en) 1993-06-23 1997-10-14 Cabrera Garrido; Juan Injectable microfoam containing a sclerosing agent
DE69418286T2 (en) 1993-06-23 1999-10-14 Btg Int Ltd Injectable microfoam that contains a sclerosing agent
ES2068151A1 (en) 1993-06-23 1995-04-01 Cabrera Garrido Juan Injectable microfoam containing a sclerosing agent.
WO1995000120A1 (en) 1993-06-23 1995-01-05 Juan Cabrera Garrido Injectable microfoam containing a sclerosing agent
EP0656203A1 (en) 1993-06-23 1995-06-07 Juan Cabrera Garrido Injectable microfoam containing a sclerosing agent
US5623085A (en) 1994-09-23 1997-04-22 Rohm And Haas Company Method for reducing microfoam in a spray-applied waterborne composition
US5902225A (en) 1994-10-11 1999-05-11 Monson; James A. Post foamable multiple-sequential-foaming composition
WO1996025194A1 (en) 1995-02-17 1996-08-22 Durand Limited Medication and apparatus and method of applying medication
WO2000024649A1 (en) 1997-05-07 2000-05-04 Giltech Limited Packaging system for mixing and dispensing multicomponent products
WO1999043371A1 (en) 1998-02-27 1999-09-02 Alain Monfreux Device for producing foam in a syringe body
FR2775436A1 (en) 1998-02-27 1999-09-03 Alain Monfreux Syringe for parenteral administration of substance in foam form
EP0997396A1 (en) 1998-10-28 2000-05-03 Kurt Vogelsang GmbH Cap for two-components aerosol container
WO2000066274A1 (en) 1999-05-03 2000-11-09 Francisco Javier Garcia Mingo Device for producing foamed sclerosing agent
WO2000072821A1 (en) 1999-05-26 2000-12-07 Btg International Limited Generation of therapeutic microfoam
US6561237B1 (en) 2000-11-28 2003-05-13 Brasscorp Ltd. Apparatus and method for urging fluid into a pressurized system

Non-Patent Citations (99)

* Cited by examiner, † Cited by third party
Title
A. Lemaire et al., "Effect of Intra-arterial oxygen injection on blood cholesterol", Therapie, vol. 13, pp. 395-399, 1958, with Abstract in English.
A. Ochsner et al., "Comparative Value of Intravenous Sclerosing Substances", Archives of Surgery, vol. 29, No. 3, pp. 397-416, Sep. 1934.
A. Schmler, "Clinical Comparison of Sclerosing Solutions in Injection Treatment of Varicose Veins, Delayed Slough: Recurrence of Varices", The American Journal of Surgey, vol. XXXVI, No. 1, pp. 389-398, Apr. 1937.
B. Ya Varshavskii, "Mechanism of Changes in Renal Activity Following intravenous oxygen", vol. 53, No. 2, pp. 173-177, 1967, with Abstract in English.
De L'Academie des Sciences, Conformement A Une Decision de L'Academie, pp. 890-892, Jan. 1930 and translation into English.
DVD #1 and #2 containing video clips shown during interview of Jan. 7, 2004.
E. J. Orbach, "Contributions to the Therapy of the Varicose Complex", Journal of the International College of Surgeons, pp. 765-771, Jun. 1950.
E. J. Orbach, "The Place of Injection Therapy in the Treatment of Venous Disorders of the Lower Extremity-with Comments on its Technique", Presented at the Annual Meeting of the International College of Angiology, London, pp. 18-23, Jul. 1965.
E. Orbach, "Leg Ulcers of Vascular Origin and Their Therapy" The American Journal of Surgery, vol. LXXXI, No. 5, pp. 568-572, May 1951.
E.J. Orbach et al.; "The Thrombogenic Property of Foam of a Synthetic Anionic Detergent (Sodium Tetradecyl Sulfate N.N.R.)", Angiol 1, pp. 237-243; 1950.
E.J. Orbach, "Schlerotherapy of Varicose Veins", American Journal of Surgery, vol. LXVI, No. 3, pp. 362-366, Dec. 1944.
E.J. Orbach; "Sclerotherapy of Varicose Veins-Utilization of an Intravenous Air Block"; American Journal of Surgery; vol. LXVI, No. 3, pp. 362-366; Dec. 1944.
F.B. Cockett, "Arterial Complications during Surgery and Sclerotherapy of Varicose Veins", Phlebology, vol. 1, pp. 3-6, 1986.
F.W. Runnicliffe et al., "The Intravenous Injection of Oxygen Gas as a Therapeutic Measure", Lancet, vol. II, pp. 321-323, 1916, with Abstract in English.
G. de Takats et al., "Division of the Popliteal Vein In Deep Venous Insufficiency of the Lower Extremities", Society for Vascular Surgery Issue, vol. 29., No. 3, pp. 342-354, Mar. 1951.
G. de Takats et al., "The Injection Treatment of Varicose Veins", Surgery, Gynecology and Obstetrics, vol. L, No. 3, pp. 545-561, Mar. 1930.
G. de Takats, "Ambulatory Ligation of the Saphenous Vein", The Journal of the American Medical Association, vol. 94, No. 16, pp. 1194-1197, Apr. 19, 1930.
G. Galata, "Intravenous Injection of Oxygen in Dogs", Archivio di Fisiologia, vol. 21, pp. 331-350, 1923, with Abstract in English.
G. Mayer, "The Treatment of Varicose Veins from the point of View of Sclerotherapy, in particularly on the Basis of Varicophtine", Münchener Medizinische Wochenschrift, vol. 16, No. 20, Columns 1037-1039, Jan. 1952 and translation into English.
G. Miserey et al., "Sclerose Sous Echographie Dans Certaines Zones a Risques", Phlebologie, vol. 44, No. 1, pp. 85-96, 1991.
German Nullity Action Complaint filed Jul. 27, 2001 and translation into English.
German Nullity Action Decision by German Court in English dated Feb. 4, 2003.
German Nullity Action English Translation of the Substantiation of Appeal to the Federal Court of Justice on Sep. 26, 2003.
German Nullity Action First Brief filed Dec. 3, 2001 and translation into English.
German Nullity Action Kreusler Brief filed Jan. 27, 2003 and translation into English.
German Nullity Action Supplemental Brief filed Dec. 31, 2002 and translation into English.
German Nullity Action; English Translation of the Reply to appeal dated Feb. 12, 2004.
H. Biegeleisen, "Fatty Acid Solutions for the Injection Treatment of Varicose Veins", Annals of Surgery, vol. CV, pp. 610-615, 1937.
H. Harkins et al., "Embolism by Air and Oxygen: Comparative Studies", Proceedings of the Society for Experimental Biology and Medicine, vol. 32, pp. 178-181, 1934-35.
H. Jausion, "Glycerine Chromee et Sclerose des Ectasies Veineuses", La Presse Medicale, No. 53, pp. 1061-1063, Jul. 5, 1933.
H. Leonhardt, "On the Treatment of Extensive Formation of Varicose Veins with Ligature of the v. Saphena and Varicoid Injection Through Ditally Inserted Ureteral Catheter", Ärztliche Wochenschrift, vol. 7, No. 3, pp. 56-58, Jan. 1952 and translation into English.
H. Rogge, "On the dangers of sclerosing recurring varicose veins", Deutsche Medizinische Wochenschrift, No. 9, p. 301, 1950 and translation into English.
H. Wefers et al., "Results of Injection Treatment with Regard to Extreme Varication", Zentralblatt für Chirurgie, Issue No. 43, pp. 1825-1828, 1952 and translation into English.
H.E. Lockhart-Mummery et al., "Varicose Ulcer-A Study of the Deep Veins with Special Reference to Retrograde Venography", The British Journal of Surgery, vol. XXXVIII, No. 151, pp. 284-295, Jan. 1951.
H.G. Oden, "Can the Results of the Treatment of Varicose Vains and Ulcus Cruris be Improved?", Münchener, Medizinische Wochenschrift, vol. 22, No. 8, pp. 364, Jan. 1952 and translation into English.
I. Singh, "Life Without Breathing", Arch. int. Pharmacodyn., vol. CXXXVII, No. 3-4, pp. 318-330, 1962.
I.S. Tunick et al., "Sodium Morrhuate as a Sclerosing Agent in the Treatment of Varicose Veins", Annals of Surgery, vol. XCV, pp. 734-737, 1932.
Jan-Christoph G.R. Wollmann, MD, "The History of Sclerosing Foams", Dermatol Surg. vol. 30, No. 5, pp. 694-703, May 2004.
K. Biegeleisen et al., "Inadvertent Intra-Arterial Injection Complicating Ordinary and Ultrasound-Guided Sclerotherapy", Phlebology, vol. 19, pp. 953-958, 1993.
K. Sigg, "Newer Aspects of the Technique of Treating Varicosities", Therapeutishce Umschau, vol. 6, pp. 127-134, 1949 and translation into English.
K. Sigg, "The Foamed Rubber Compression for Phlebitis and for Phlebitic and Varicose Complications", Die Medizinische, No. 27-28, pp. 910-915, Jul. 1952 and translation into English.
K. Sigg, "The Treatment of Varicosities and Accompanying Complications", Angiology, The Journal of Vascular Diseases, vol. 3, No. 5, pp. 355-379, Oct. 1952.
K10-E. Rabe et al.; "Guidelines to Sclerosing Treatment of Varicose Veins"; Leitlinien der DGP, Phlebologie; vol. 6, pp. 154-158; 2001 and translation into English.
K11-DE 3417182 C2 and EP 0 054 728 and translations into English.
K12-K. Sigg, "Newer Aspects of the Technique of Treating Varicosities", Therpeutishce Umschau, vol. 6, pp. 127-134, 1949 and translation into English.
K13-M. Schadeck; "Duplex Controlled Sclerosing Treatment of the Great Saphenous Vein"; Phlebol; vol. 25, pp. 78-82; 1996 and translation into English.
K14-R. Rowden-Foote; "Varicose Veins Hemorrhoids and Other Conditions-Their Treatment by Injection"; London, H.K. Lewis & Co. Ltd.; pp. 13-45, 106-119; 1944.
K15-A. Ree; "The Treatment of Varicose Veins with Etamolin Foam"; Acta Dermato-Venereologica; vol. 39, pp. 428-432; 1959.
K16-E.J. Orbach et al.; "The Thromobogenic Property of Foam of a Synthetic Anionic Detergent (Sodium Tetradecyl Sulfate N.N.R.)", Angiol 1, pp. 237-243; 1950.
K17-M.D.H.-D. Bock; "Varicosis and its Therapy"; Ärztliche Praxis; XIX vol., No. 60, pp. 2146-2148; Jul. 29, 1967 and translation into English.
K18-O. Henschel;"Die Varizenverördening-Verördungstherapie mit Aethoxysklerol-Kreussler"; p. 22; 1968 and translation into English.
K19-13 Pr. Dr. rer. nat. Reinhard Höhler ; "The Expression <<Micro Foam>> is Neither Generally Known to Experts in the Field nor Well-defined"; Laboratoire de Physique de Milieux Diviséet Interfaces Université de Marne-la-Vallée and translation into English.
K1-Von P. Flückiger, "Nicht-operative retrograde Varicenverödung mit Varsylschaum", Schweizerische Medizinische Wochenschrift, No. 48, pp. 1368-1370, (1956) with English translation.
K20-Chronologia der Schaumverödung.
K21-J. Orbach, "Sclerotherapy of varicose Veins", American Journal of Surgery, vol. LXVI, No. 3, pp. 362-366, Dec. 1944.
K22-J.R. Cabrera Garrido et al., "Extending the Limits of Sclerotherapy: New Sclerosing Products", Phlébp;pgoe, vol. 50, No. 2, pp. 181-188, 1997.
K23-J. Cabrera; "Application Techniques for Sclerosant in Micro-Foam Form"; pp. 39-44.
K24-Video (VHS) tape of Compression Sclerotherapy, H.R., Bernbach, M.D. and English Translation of the Documentation Accompanying the Video K24; pp. 1-16.
K25-Dr. J.C. Wollmann et al.; Evaluation of the Test; Kreussler Pharma; pp. 17-28, Jan. 29, 2003.
K26-Pr. Dr. R. Höhler ; "The Indication of the Rotation Speed and the Duration of the Rotation is not Sufficient for Foams Produced by a Rotating Brush to be Able to Produce a Foam that Has Well-Defined Properties and that Can Be Reproduced."; and translation into English.
K27-Pr. Dr. R. Höhler; "Comparison Between Three-Dimensional Foams and Two-Dimensional Foams Which Are Produced by Squashing a Three-Dimensional Foam between a Two-Dimensional Foam."; Laboratoire de Physique de Milleux Divisés et Interfaces Université de Marne-la-Vallée and translation into English.
K2-H. Mayer et al., "On the aetiology and treatment of varices of the lower extremities", Angiology, Chirurgische Praxis, pp. 521-528, (1957) with English translation.
K3-Meyers'Encyclopedia, 5<SUP>th </SUP>Edition, vol. 15, pp. 386 (1985) with English translation.
K4-Von P. Flückiger et al., "Beitrag sur Technik der ambulanten Varizenbehandlung", No. 12, pp. 617-621, Mar. 23, 1963.
K5-Dr. Med. Jo{hacek over (ze Baridevic; "Varicosclerozation in Phlebological Practice"; The Journal for Doctors, in Clinical and Practice; XXI vol. No. 3, pp. 126-136; Jan. 11, 1989, and translation into English.
K6-W. Gillesberger; "The Equipment of the Dermatologist Working in the Field of Phlebology", the Journal for Skin Diseases; vol. 44 (18), pp. 669-674; 1969 and translation into English.
K7-Dr. E. Lunkenheimer; Letter to Chem. Fabrik Kreussler & Co.; Mar. 20, 1967 and translation into English.
K8-Gianni Belcaro; "Micro-sclerotherapy"; Sclerotherapy in Venous Disease; pp. 89-95; 2002.
K9-M. Schadeck; "Ultrasound-controlled Sclerotherapy of the Great Saphenous Veins"; Phlébologie; vol. 46, No. 4, pp. 673-682, 1993 and tranlsation into English.
L. Ferguson, "Ligation of Varicose Veins, Ambulatory Treatment Preliminary to Sclerosing Injections", Annals of Surgery, vol. CII, pp. 304-314, 1935.
L. Karmazsin et al., "Experimental Study of Lipid Peroxidation Following Intravenous Oxygen", Kiserletes Orvostudomany, vol. 39, pp. 342-348, 1987, with Abstract in English.
L. Moszkowiez, "Treatment of Varicose Veins with Sugar Injections, combined with vein ligation", Zentralblatt fur Chirurgie, No. 28, pp. 1731-1736, 1927 and translation into English.
L. Reiner, "The Activity of Anionic Surface Active Compounds in Producing Vascular Obliteration", Surface Active Sclerosing Agents, Proceedings of the Society for Experimental Biology and Medicine, vol. 62, pp. 49-54, May-Jun. 1946.
M. Battezzati et al., "Treatment of Lower Limb Varices with Multiple Endermic Ligations and Sclerosant Injections Combined or not with Stripping of the Long Saphenous Vein's higher region", Minerva Chirurgica, pp. 936-939, 1952 and translation into English.
M. Mairano, "Metodo combinato chirurgico-sclerosante o metodo sclerosante semplice nel trattamento delle varici essenziali?" Minerva Chirugica, vol. VI, No. 16, pp. 244-247, May 1951.
M. Schadeck et al., "Echotomographie de la Sclerose", Phlebologie, vol. 44, No. 1, pp. 111-130, 1991.
Meyers's Encyclopedia 5<SUP>th </SUP>Edition, 1895, vol. 15, pp. 386.
P. Jaeger, "The Current Treatment Standard for Crural Ulcer and Varices", Deutsche Medizinische Wochenschrift, vol. 77, No. 14, pp. 421-425, Apr. 4, 1952 and translation into English.
P. Piulaches et al., "Pathogenic Considerations on Varicose Veins Developed in Pregnancy", Lyon Chirurigical, Bulletin official de la Socirte de Chriurgie de Lyon, vol. 47, No. 3, pp. 263-278, Apr. 1952 and translation into English.
P. Thibault et al., "Recurrent Varicose Veins", Phlebology, vol. 18, pp. 895-900, 1992.
R. Bayeux, "Comparative Resistance of Dog and Rabbit to Intravenous Injection of Oxygen", Compt. Rend. vol. 156, pp. 1329-1331, 1913, with Abstract in English.
R. de Somer-Leroy et al., "Echographie du Creux-Poplite Recherche D'Une Arteriole Petite Saphene Avant Sclerotherapie", Phlebologie, vol. 44, No. 1, pp. 69-78, 1991.
R. E. Weston et al., "The Influence of Denitrogenation on the Response of Anesthetized Dogs to Intravenously Injected Oxygen", vol. 26, pp. 837-848, 1946.
R. Foote, "Treatment", Varicose Veins, Chapter 5, p. 65 and 86, 1949.
R. Jung, "Injection Treatment of Varicose Veins", Praxis, 195-198, 1950 and translation into English.
R. M. Knight et al., "Ultrasonic Guidance of Injections into the Superficial Venous System", Phlebology, pp. 339-341, 1989.
R. Rowden-Foote; "Varicose Veins Hermorrhoids and Other Conditions-Their Treatment by Injection"; London, H.K. Lewis & Co. Ltd.; pp. 13-45, 106-119; 1944.
R. Zingg, "Experimental tests with the new sclerosing agent "Geigy"", pp. 1-9, 1948.
R.M. Moore et al., "Injections of Air and Carbon Dioxide into a Pulmonary Vein", Annals of Surgery, vol. 112, pp. 212-218, 1940.
R.S. Handley, "The Treatment of Varicose Veins", The Practitioner-Diseases of the Veins, No. 993, vol. 166, pp. 228-235, Mar. 1951.
S. Efuin et al., "Oxygen Parameters of Blood and Tissues during Intravascular Oxygenation of the Organism", Eksperimental'naya Khirurgiya I Anesteziologiya, vol. 5, pp. 183-186, 1974, with Abstract in English.
S. Efuin et al., Oxygen Parameters of Blood and Tissues during Intravascular Oxygenation of the Organism, Eksperimental'naya Khirurgiya I Anesteziologiya, vol. 5, pp. 71-74, 1974, with Abstract in English.
Sigg, "Regarding treatment of varicose veins and their complications", Dermatologica, vol. 100, p. 317, 1950 and translation into English.
V. Gorisch et al., "Appearance of intravenously given radioactive oxygen in expired air", Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie, vol. 238, pp. 106-107, 1960, with Abstract in English.
V. Gorisch et al., "Expiration of labeled oxygen after intravenous insufflation", Medicina Experimentalis, vol. 1, pp. 333-338, 1959, Abstract in English.
Vin, "Echo-Sclerotherapy of the Small Saphenous Vein", Phlebologie, vol. 44, No. 1, pp. 79-84, 1991 with Abstract in English.
W. Heyerdale et al., "Management of Varicose Veins of the Lower Extremities", Annals of Surgery, vol. 114, pp. 1042-1049, 1941.
Written commentary tracking the DVDs submitted herein.
Z.B. Shafi et al., "Factors Affecting High Shear Preparation of Albumin Microspheres", Pharmaceutical Sciences Research GRoup, p. 144P, 1990.

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080145401A1 (en) * 1999-05-26 2008-06-19 Tariq Osman Generation of Therapeutic Microfoam
US20060049269A1 (en) * 1999-05-26 2006-03-09 Tariq Osman Generation of therapeutic microfoam
US8091801B2 (en) 1999-05-26 2012-01-10 Btg International Limited Generation of therapeutic microfoam
US7604185B2 (en) 1999-05-26 2009-10-20 Btg International Ltd. Generation of therapeutic microfoam
US20090256006A1 (en) * 1999-05-26 2009-10-15 Tariq Osman Generation of therapeutic microfoam
US20090041827A1 (en) * 1999-05-26 2009-02-12 Btg International Ltd. Therapeutic Microfoam
US20070031345A1 (en) * 2000-11-24 2007-02-08 Harman Anthony D Generation of therapeutic microfoam
US7842283B2 (en) 2000-11-24 2010-11-30 Btg International Limited Generation of therapeutic microfoam
US20040156915A1 (en) * 2000-11-24 2004-08-12 Harman Anthony David Generation of therapeutic microfoam
US7842282B2 (en) 2000-11-24 2010-11-30 Btg International Limited Generation of therapeutic microfoam
US20070031346A1 (en) * 2000-11-24 2007-02-08 Harman Anthony D Generation of therapeutic microfoam
US8512680B2 (en) 2001-08-08 2013-08-20 Btg International Ltd. Injectables in foam, new pharmaceutical applications
US20080031827A1 (en) * 2001-08-08 2008-02-07 Maria Garcia-Olmedo Dominguez Injectables in foam. New Pharmaceutical applications
US20060062736A1 (en) * 2003-11-17 2006-03-23 Wright David D I Therapeutic foam
US8048439B2 (en) 2003-11-17 2011-11-01 Btg International Ltd. Therapeutic foam
US7731986B2 (en) 2003-11-17 2010-06-08 Btg International Ltd. Therapeutic foam
US7763269B2 (en) 2003-11-17 2010-07-27 Btg International Ltd. Therapeutic foam
US8323677B2 (en) 2003-11-17 2012-12-04 Btg International Ltd. Therapeutic foam
US20070003488A1 (en) * 2003-11-17 2007-01-04 Wright David D I Methods of preparing a foam comprising a sclerosing agent
US20060280690A1 (en) * 2003-11-17 2006-12-14 Wright David D I Methods of preparing a foam comprising a sclerosing agent
US20070104651A1 (en) * 2003-11-17 2007-05-10 Wright David D I Therapeutic foam
US20070003489A1 (en) * 2003-11-17 2007-01-04 Wright David D I Therapeutic foam
US20090124704A1 (en) * 2005-05-13 2009-05-14 William John Jenkins Therapeutic foam
US8703827B2 (en) 2005-05-13 2014-04-22 Btg International Ltd. Therapeutic foam
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
US9844520B2 (en) 2015-02-27 2017-12-19 John Daniel Dobak, III Reduction of adipose tissue
US10485767B2 (en) 2015-02-27 2019-11-26 John Daniel Dobak, III Reduction of adipose tissue
US11065210B2 (en) 2015-02-27 2021-07-20 10Xbio, Llc Reduction of adipose tissue

Also Published As

Publication number Publication date
EP0656203A1 (en) 1995-06-07
USRE40640E1 (en) 2009-02-17
ES2131689T3 (en) 1999-08-01
ES2068151A1 (en) 1995-04-01
GR3030248T3 (en) 1999-08-31
WO1995000120A1 (en) 1995-01-05
DE69418286D1 (en) 1999-06-10
US5676962A (en) 1997-10-14
AU7001294A (en) 1995-01-17
EP0656203B3 (en) 2011-01-26
DE69418286T2 (en) 1999-10-14
ES2068151B1 (en) 1995-11-16
ES2131689T7 (en) 2012-03-16
ATE179598T1 (en) 1999-05-15
EP0656203B1 (en) 1999-05-06
DK0656203T3 (en) 1999-11-01

Similar Documents

Publication Publication Date Title
USRE38919E1 (en) Injectable microfoam containing a sclerosing agent
EP1701701B1 (en) Methods of preparing a foam comprising a sclerosing agent
Cabrera et al. Treatment of varicose long saphenous veins with sclerosant in microfoam form: long-term outcomes
CN104902935B (en) Hemostatic foam
Cercek et al. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.
Johns et al. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Eckmann et al. Microvascular embolization following polidocanol microfoam sclerosant administration
Masaki et al. The destructive effects of sclerosant ethanolamine oleate on mammalian vessel endothelium
Rapold et al. Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator
Goldhaber et al. Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator
US7314466B2 (en) Minimally invasive vascular surgery
Do et al. Catheter thrombolysis with streptokinase, urokinase, and recombinant tissue plasminogen activator for peripheral arterial occlusion
Goto et al. Effect of high-dose of methylprednisolone on tourniquet ischaemia
Thomas Prevention of post-operative thrombosis by low molecular weight heparin in patients undergoing hip replacement
Farret et al. Preparation, characterization and in vitro thrombolytic activity of a novel streptokinase foam
US8512680B2 (en) Injectables in foam, new pharmaceutical applications
Taga et al. The effects of intra-arterially injected adriamycin on microvascular anastomosis
Cabrera et al. Sclerotherapy in vascular malformations
Goldhaber et al. Tissue plasminogen activator and acute pulmonary embolism
Cade et al. Effects of thrombolytic therapy on hemorrhage from post-operative wounds
Savitha et al. Foam Sclerotherapy
Verheugt Optimalization of Thrombolytic Therapy for Acute Myocardial Infarction
NO864382L (en) MEASURES FOR IMPROVING PROTEIN ABSORPTION.
Cabrera Dr J. Cabrera is the creator of the patented polidocanol microfoam
Bergan What’s the Story with Foam Sclerotherapy?

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY